FDG PET/CT VỚI TIÊU CHÍ HOPKINS TRONG ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

Quốc Lê Nho; Hạnh Lê Phạm Mỹ; Cảnh Nguyễn Xuân

doi:10.59354/ydth175.2023.71

Keywords:

non-small cell lung cancer, PET/CT, FDG, Hopkins criteria

Abstract

Objective: Many imaging modalities are extensively applied for diagnosis and follow-up in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the role of PET/CT (Positron Emission Computed Tomography) with F-18 Fluorodeoxyglucose (FDG) based Hopkins criteria for therapy response in NSCLC.

Patients and methods: Retrospective study of NSCLC patients who underwent FDG PET/CT before and after chemotherapy and/or radiation therapy to analyzed the efficacy of FDG PET/CT using the 5 points scale of Hopkins criteria.

Results: The study included 23 patients with NSCLC (18 male and 5 female).

Before specific treatment, 22 patients with primary lung lesion uptaked FDG at 5 points and 1 patient with 4 points according to Hopkins criteria. After treatment, 5 patients demonstrated primary lung lesion with FDG uptake at 5 points, 2 at 4 points, 2 at 3 points and 14 without primary lung lesions.

Six patients (26.1%) showed complete response, 5 (21.7%) partial response, 4 (17.4%) stable disease and 8 (34.8%) progression disease.

Conclusions: The pilot study suggested FDG PET/CT based on Hopkins criteria appropriate for assessment of NSCLC treated with chemotherapy and/or radiotherapy.

References

Globocan (2020): Incidence, Mortality and Prevalence by cancer site in Viet Nam https://gco.iarc.fr/today/data/ factsheets/populations/704-viet-nam-fact-sheets.pdf.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer;45(2):228-47.

O JH, Lodge MA, Wahl RL (2016). Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology;280(2):576-584.

Nguyễn Xuân Cảnh và cộng sự (2018): Hình ảnh 18FDG PET/CT trong đánh giá đáp ứng điều trị ung thư. Tạp chí Y dược lâm sàng 108. Tập 13 – Số đặc biệt 7/2018, tr. 9-21.

Sheikhbahaei S, Mena E, Marcus C, Wray R et al (2016). 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. J Nucl Med.;57(6):855-60.

Fangfang Chao, Hong Zhang (2012). PET/CT in the Staging of the Non-Small-Cell Lung Cancer. J Biomed Biotechnol. 783739. Published online 2012.

Chao F, Zhang H (2012). PET/ CT in the staging of the non-small-cell lung cancer. J Biomed Biotechnol;2012:783739.

Gould MK, Kuschner WG, Rydzak BA, et al. (2003): Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med,139(11):879–892.

Young H, Baum R, Cremerius U et al (1999). Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer;35(13):1773-82.